Table 2.
Studies | SE | SP | AUC | TA | NPV | PPV | |||
---|---|---|---|---|---|---|---|---|---|
[number] | [%] | [%] | [partial]a | [%] | [0.5%]b | [5%]c | [0.5%]b | [5%]c | |
HPLC | 15 | 94 | 93 | 0.947 | 93–94 | n.a. | n.a. | ||
IA | 11 | 91 | 93 | 0.911 | 91–93 | n.a. | n.a. | ||
Supine | 10 | 95* | 95** | 0.942 | 95–95 | 0.9997 | 0.9972 | 0.0872 | 0.5000 |
Seated | 10 | 89* | 94 | 0.913 | 89–94 | 0.9994 | 0.9939 | 0.0694 | 0.4384 |
Urine | 11 | 93 | 90** | 0.932 | 90–93 | 0.9996 | 0.9959 | 0.0446 | 0.3286 |
SE sensitivity; SP specificity; TA test accuracy range (for prevalence ranges between 0.0–1.0); NPV negative predictive value; PPV positive predictive value; n.a. not assessed
supine versus seated p<0.02;
supine versus 24-h urine p<0.03
for details see Methods
prevalence of P/PGL among hypertensive subjects (0.2–0.6%)
prevalence of P/PGL in subjects with incidentaloma